

# Nicaragua

## Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-04-19)



### I. Key data on HPV and HPV-related cancers



Nicaragua has a population of 2.20 millions women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 934 women are diagnosed with cervical cancer and 424 die

from the disease. Cervical cancer ranks as the 1st most frequent cancer among women in Nicaragua and the 1st most frequent cancer among women between 15 and 44 years of age. Data is not yet available on the HPV burden in the general population of Nicaragua. However, in Central America, the region Nicaragua belongs to, about 4.7% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 63.1% of invasive cervical cancers are attributed to HPVs 16 or 18.

**Table 1. Crude incidence rates of HPV-related cancers**

	Male	Female
Cervical cancer	-	31.0
Anal cancer	-	-
Vulva cancer	-	-
Vaginal cancer	-	-
Penile cancer	-	-
Pharynx (excluding nasopharynx)	0.7	0.1


**Table 2. Burden of cervical cancer**

	Incidence	Mortality
Annual number of new cases/deaths	934	424
Crude rate	31.0	14.1
Age-standardized rate	36.2	18.3
Cumulative risk 0-74 years (%)	3.5	2.0
Ranking of cervical cancer (all years)	1st	1st
Ranking of cervical cancer (15-44 years)	1st	1st

**Table 3. Burden of cervical HPV infection Nicaragua**

	No. Tested	% (95% CI)
HPV prevalence in women with normal cytology	4340	9.8 (8.9-10.7)
HPV 16/18 prevalence:		
Normal cytology	-	-
Low-grade cervical lesions	79	7.6 (3.5-15.6)
High-grade cervical lesions	108	33.3 (25.2-42.7)
Cervical cancer	19	57.9 (36.3-76.9)

**Figure 1. Comparison of the ten most frequent HPV oncogenic types in Nicaragua among women with and without cervical lesions**



\*No data available. No more types than shown were tested or were positive.

# Nicaragua

## Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-04-19)



### II. Complementary data on cervical cancer prevention

**Table 4. Factors contributing to cervical cancer (co-factors)**

Smoking prevalence (%), women	-
Total fertility rate (live births per women)	2.7
Hormonal contraception use (%) (pill, injectable or implant), among women	37.3
HIV prevalence (%), adults (15-49 years)	0.3 [0.2 - 0.4]

**Table 5. Sexual behaviour**

<b>MEN</b>	
Percentage of 15-year-old who have had sexual intercourse	-
Range of median age at first sexual intercourse	-
<b>WOMEN</b>	
Percentage of 15-year-old who have had sexual intercourse	-
Range of median age at first sexual intercourse	16.9-18.4


**Table 6. HPV vaccine introduction**

HPV vaccination programme	No Program
Date of HPV vaccination routine immunization programme start	-
HPV vaccination target age for routine immunization	-
Full course HPV vaccination coverage for routine immunization:	-
% (calendar year)	-

**Table 7. Cervical screening practices and recommendations**

Cervical cancer screening coverage, % (age and screening interval, reference)	31.5% (All women aged 15-49 screened every 1y, ENDESA 2006-2007 Nicaragua)
Screening ages (years)	25-64 (cytology), 30-50 (VIA)
Screening interval (years) or frequency of screens	Cytology/VIA every 3 years after 3 consecutive annual negative tests

**Figure 2. Estimated coverage of cervical cancer screening in Nicaragua, by age and study**



#### Contact information:

ICO HPV Information Centre  
 Institut Català d'Oncologia  
 Avda. Gran Via de l'Hospitalet, 199-203  
 08908 L'Hospitalet de Llobregat (Barcelona, Spain)  
 e-mail: [info@hpvcentre.net](mailto:info@hpvcentre.net)  
 internet address: [www.hpvcentre.net](http://www.hpvcentre.net)